Eli Lilly/$LLY

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Ticker

$LLY
Sector

Primary listing

NYSE

Employees

47,000

Eli Lilly Metrics

BasicAdvanced
$759B
55.26
$15.29
0.47
$5.80
0.71%

What the Analysts think about Eli Lilly

Analyst ratings (Buy, Hold, Sell) for Eli Lilly stock.

Bulls say / Bears say

The US FDA approved Inluriyo for advanced breast cancer after a late-stage trial showed a 38% reduction in disease progression or death, broadening Lilly’s oncology portfolio and near-term revenue potential (Reuters)
Analysts expect Lilly to report Q2 earnings of $5.57 per share on $14.71 billion in revenue, driven by strong sales of market-leading weight-loss drug Zepbound and diabetes treatment Mounjaro (Reuters)
Orforglipron, Lilly’s oral GLP-1 obesity candidate, outperformed Novo’s Rybelsus in recent head-to-head trials and is forecast to achieve up to $10 billion in peak annual sales with global filings planned imminently (Reuters)
Lilly halted its mid-stage bimagrumab trial aimed at preserving muscle mass alongside its blockbuster Zepbound, reflecting potential pipeline setbacks and intensifying competition in obesity adjunct therapies (Reuters)
A federal appeals court upheld a $183.7 million Medicaid fraud judgment against Lilly for underreporting drug price increases, underscoring significant legal liabilities and reputational risks (Reuters)
Novo Nordisk expects an FDA decision on its oral obesity candidate later this year, posing a direct competitive threat that could cap orforglipron’s market penetration (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2025.

Eli Lilly Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Eli Lilly Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $LLY

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs